X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (22000) 22000
Newsletter (157) 157
Newspaper Article (136) 136
Book Chapter (37) 37
Magazine Article (36) 36
Book / eBook (26) 26
Conference Proceeding (6) 6
Dissertation (4) 4
Government Document (4) 4
Trade Publication Article (3) 3
Book Review (2) 2
Web Resource (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19872) 19872
male (11219) 11219
female (10535) 10535
middle aged (8043) 8043
kidney neoplasms - drug therapy (7658) 7658
oncology (7068) 7068
aged (6506) 6506
adult (5780) 5780
cancer (5681) 5681
kidney neoplasms - pathology (5421) 5421
carcinoma, renal cell - drug therapy (5375) 5375
animals (3603) 3603
antineoplastic agents - therapeutic use (3201) 3201
treatment outcome (3111) 3111
carcinoma, renal cell - pathology (2960) 2960
urology & nephrology (2908) 2908
renal cell carcinoma (2793) 2793
care and treatment (2418) 2418
metastasis (2380) 2380
prognosis (2278) 2278
tumors (2249) 2249
carcinoma, renal cell (2201) 2201
antineoplastic combined chemotherapy protocols - therapeutic use (2076) 2076
retrospective studies (2000) 2000
mice (1992) 1992
chemotherapy (1957) 1957
kidney neoplasms - therapy (1907) 1907
kidney cancer (1867) 1867
kidneys (1860) 1860
aged, 80 and over (1847) 1847
kidney neoplasms - surgery (1806) 1806
survival (1771) 1771
therapy (1755) 1755
sunitinib (1713) 1713
risk factors (1704) 1704
research (1687) 1687
carcinoma, renal cell - secondary (1685) 1685
antineoplastic agents - adverse effects (1599) 1599
neoplasm metastasis (1576) 1576
interferon-alpha (1540) 1540
kidney neoplasms - metabolism (1534) 1534
immunotherapy (1521) 1521
surgery (1505) 1505
cell line, tumor (1494) 1494
analysis (1487) 1487
nephrectomy (1466) 1466
kidney transplantation (1448) 1448
adolescent (1423) 1423
child (1389) 1389
kidney neoplasms - mortality (1388) 1388
expression (1376) 1376
pharmacology & pharmacy (1369) 1369
kidney neoplasms - genetics (1367) 1367
medicine & public health (1349) 1349
transplantation (1334) 1334
neoplasms - drug therapy (1330) 1330
kidney - drug effects (1328) 1328
health aspects (1314) 1314
carcinoma, renal cell - therapy (1258) 1258
carcinoma (1230) 1230
carcinoma, renal cell - metabolism (1217) 1217
kidney (1178) 1178
time factors (1176) 1176
urology (1176) 1176
patients (1172) 1172
follow-up studies (1166) 1166
drug therapy (1165) 1165
combined modality therapy (1164) 1164
apoptosis (1153) 1153
carcinoma, renal cell - genetics (1113) 1113
neoplasm staging (1101) 1101
carcinoma, renal cell - mortality (1089) 1089
child, preschool (1072) 1072
disease-free survival (1061) 1061
antineoplastic agents - administration & dosage (1059) 1059
kidney diseases (973) 973
antineoplastic agents - pharmacology (956) 956
sorafenib (952) 952
dose-response relationship, drug (951) 951
diagnosis (930) 930
survival rate (926) 926
cancer therapies (925) 925
drug administration schedule (917) 917
indoles - therapeutic use (913) 913
carcinoma, renal cell - surgery (905) 905
pyrroles - therapeutic use (902) 902
lung neoplasms - drug therapy (894) 894
medicine (888) 888
survival analysis (884) 884
hematology (880) 880
proteins (873) 873
immunology (858) 858
infant (827) 827
kidney neoplasms - diagnosis (825) 825
niacinamide - analogs & derivatives (804) 804
antineoplastic combined chemotherapy protocols - adverse effects (784) 784
clear cell-type renal cell carcinoma (782) 782
kidney - pathology (782) 782
antineoplastic agents (781) 781
research article (773) 773
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (7) 7
Online Resources - Online (3) 3
Gerstein Science - Bindery (1) 1
Gerstein Science - Periodical Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (20724) 20724
Japanese (686) 686
German (455) 455
French (372) 372
Russian (128) 128
Spanish (121) 121
Italian (82) 82
Chinese (66) 66
Polish (50) 50
Hungarian (25) 25
Czech (20) 20
Dutch (15) 15
Danish (11) 11
Portuguese (10) 10
Ukrainian (9) 9
Hebrew (5) 5
Croatian (4) 4
Swedish (4) 4
Turkish (3) 3
Finnish (2) 2
Korean (2) 2
Norwegian (2) 2
Serbian (2) 2
Arabic (1) 1
Lithuanian (1) 1
Romanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 19, pp. 3167 - 3175
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 11, pp. 1904 - 1911
.... To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical... 
pembrolizumab | autoimmune | nivolumab | elderly | ipilimumab | pediatrics | pregnancy | transplant | organ dysfunction | ALLOGRAFT-REJECTION | PERFORMANCE STATUS | PD-1 BLOCKADE | OPEN-LABEL | CELL LUNG-CANCER | IPILIMUMAB THERAPY | ONCOLOGY | ADVANCED MELANOMA | BRAIN METASTASES | AUTOIMMUNE-DISEASE | T-CELLS | Lung Neoplasms - drug therapy | Melanoma - complications | Age Factors | Humans | Immunosuppressive Agents - therapeutic use | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Hepatitis C, Chronic - complications | Transplant Recipients | Neoplasms - complications | Brain Neoplasms - secondary | Squamous Cell Carcinoma of Head and Neck | Pregnancy Complications, Neoplastic - drug therapy | Female | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - complications | Graft Rejection - prevention & control | Autoimmune Diseases - complications | Head and Neck Neoplasms - drug therapy | Brain Neoplasms - drug therapy | Lung Neoplasms - complications | Neoplasms - drug therapy | Pregnancy | Carcinoma, Non-Small-Cell Lung - complications | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Hepatitis B, Chronic - complications | Carcinoma, Squamous Cell - complications | Melanoma - drug therapy | Nivolumab | HIV Infections - complications | Head and Neck Neoplasms - complications | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Renal Cell - complications | Immunocompromised Host | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Virus diseases | Care and treatment | Dosage and administration | Research | Cell death | Immunosuppressive agents | Medical research | Brain | Populations | Toxicity | Decision making | Mortality | Disorders | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Patients | Regulatory approval | Metastases | Inhibitors | Immune checkpoint | Aggregates | Lymphocytes | Safety | Autoimmune diseases | Cancer | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | CTLA-4 | LIGAND | BLOCKADE | CLINICAL ACTIVITY | PHASE-I | PD-1 | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Female | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Lungs | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 2017, Volume 123, Issue 16, pp. 3080 - 3087
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | THERAPEUTICS | FARLETUZUMAB | PLATINUM-RESISTANT OVARIAN | MONOCLONAL-ANTIBODY | COMBINATION | EPITHELIAL OVARIAN-CANCER | CHEMOTHERAPY | DELIVERY | THERAPY | ONCOLOGY | PROTEINS | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 76, pp. 84 - 92
Abstract Background Preclinical models that mimic pathological and molecular features of solitary fibrous tumour (SFT) represent an important tool to select... 
Hematology, Oncology and Palliative Medicine | Eribulin | Xenograft | Sarcoma | Ifosfamide | Mice model | Solitary fibrous tumour | Metastasis | Trabectedin | Doxorubicin | Dacarbazine | Chemotherapy | Treatment | Anthracycline | MECHANISM | PHASE-2 | IDENTIFICATION | TEMOZOLOMIDE | MESYLATE | ONCOLOGY | RECURRENT | HEMANGIOPERICYTOMA | EXPRESSION | SOFT-TISSUE SARCOMA | Humans | Middle Aged | Soft Tissue Neoplasms - drug therapy | Male | Response Evaluation Criteria in Solid Tumors | Pleural Neoplasms - drug therapy | Retroperitoneal Neoplasms - mortality | Meningeal Neoplasms - drug therapy | Retroperitoneal Neoplasms - drug therapy | Dioxoles - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Cerebellar Neoplasms - drug therapy | Dacarbazine - administration & dosage | Soft Tissue Neoplasms - mortality | Solitary Fibrous Tumors - drug therapy | Solitary Fibrous Tumors - mortality | Cerebellar Neoplasms - mortality | Ketones - administration & dosage | Survival Rate | Tetrahydroisoquinolines - administration & dosage | Pleural Neoplasms - mortality | Kidney Neoplasms - mortality | Mice, SCID | Blotting, Western | Meningeal Neoplasms - mortality | Xenograft Model Antitumor Assays | Disease-Free Survival | Animals | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Furans - administration & dosage | Analysis | Melanoma | Stem cells | Anthracyclines | Cancer
Journal Article
Pharmaceutical research, ISSN 1573-904X, 2018, Volume 35, Issue 9, pp. 1 - 20
.... Future success in therapeutics for brain metastases must take into account the adequate delivery of “active, free drug... 
Biochemistry, general | Biomedical Engineering | blood-brain barrier | Biomedicine | metastasize | Pharmacy | brain metastases | Medical Law | efflux transporters | molecularly-targeted anti-cancer agents | drug delivery | Pharmacology/Toxicology | PROPHYLACTIC CRANIAL IRRADIATION | RESISTANCE PROTEIN ABCG2 | MULTICENTER PHASE-II | EML4-ALK FUSION GENE | CHEMISTRY, MULTIDISCIPLINARY | P-GLYCOPROTEIN ABCB1 | NEGATIVE BREAST-CANCER | CELL LUNG-CANCER | MOLECULARLY TARGETED THERAPIES | PHARMACOLOGY & PHARMACY | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID CONCENTRATION | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Brain Neoplasms - pathology | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Brain Neoplasms - metabolism | Breast Neoplasms - metabolism | Brain - metabolism | Brain Neoplasms - secondary | Female | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Melanoma - metabolism | Carcinoma, Renal Cell - pathology | Melanoma - pathology | Brain Neoplasms - drug therapy | Blood-Brain Barrier - drug effects | Breast Neoplasms - drug therapy | Blood-Brain Barrier - metabolism | Brain - drug effects | Blood-Brain Barrier - pathology | Carcinoma, Renal Cell - metabolism | Animals | Breast Neoplasms - pathology | Melanoma - drug therapy | Brain - pathology | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Drug Delivery Systems - methods | Precision Medicine - methods | Drugs | Care and treatment | Drug delivery systems | Therapeutics | Brain damage | Metastasis | Permeability | Homeopathy | Materia medica and therapeutics | Vehicles | Efflux | Brain | Toxicity | Brain tumors | Central nervous system | Membrane permeability | Oncology | Success | Metastases | Medicine | Blood-brain barrier | Precision medicine | Lesions | Tumors
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 77, Issue 3, pp. 655 - 661
... standard of care, WBRT, is appropriate as the primary treatment of all patients with BMs instead of reserving WBRT for later salvage therapy, as needed... 
Radiology | Hematology, Oncology and Palliative Medicine | radiotherapy | Brain metastases | prognosis | stereotactic radiosurgery | COST-EFFECTIVENESS | PARTITIONING ANALYSIS RPA | RADIATION-THERAPY | TRIAL | ONCOLOGY | NEUROCOGNITIVE FUNCTION | RANDOMIZED PHASE-III | ACCELERATED-FRACTIONATION | SINGLE METASTASES | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Carcinoma, Non-Small-Cell Lung - radiotherapy | Gastrointestinal Neoplasms | Prognosis | Age Factors | Humans | Middle Aged | Lung Neoplasms | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - secondary | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Karnofsky Performance Status | Small Cell Lung Carcinoma - radiotherapy | Retrospective Studies | Brain Neoplasms - radiotherapy | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms | Brain Neoplasms - diagnosis | Melanoma - radiotherapy | Treatment Outcome | Brain Neoplasms - drug therapy | Melanoma - secondary | Carcinoma, Renal Cell - radiotherapy | Analysis of Variance | Carcinoma, Renal Cell - secondary | Melanoma - drug therapy | Skin Neoplasms | Selection Bias | Aged | Combined Modality Therapy - methods | Carcinoma, Non-Small-Cell Lung - drug therapy | Care and treatment | Metastasis | Patient outcomes | Analysis | SURGERY | METASTASES | NERVOUS SYSTEM | CENTRAL NERVOUS SYSTEM | MEDICINE | NUCLEAR MEDICINE | ORGANS | THERAPY | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | BODY | BRAIN | RADIOLOGY
Journal Article